​

Spruce Biosciences (SPRB) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

SPRB Stock Forecast

Spruce Biosciences (SPRB) stock forecast, based on 10 Wall Street analysts, predicts a 12-month average price target of $207.00, with a high of $254.00 and a low of $160.00. This represents a 68.27% increase from the last price of $123.02.

- $60 $120 $180 $240 $300 High: $254 Avg: $207 Low: $160 Last Closed Price: $123.02

SPRB Stock Rating

Spruce Biosciences stock's rating consensus is Hold, based on 10 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 2 Buy (20.00%), 8 Hold (80.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Hold
Total 10 0 8 2 Strong Sell Sell Hold Buy Strong Buy

SPRB Price Target Upside V Benchmarks

TypeNameUpside
StockSpruce Biosciences68.27%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts222
Avg Price Target$207.00$207.00$207.00
Last Closing Price$123.02$123.02$123.02
Upside/Downside68.27%68.27%68.27%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25--1--1
Sep, 25--1--1
Aug, 25--2--2
Jul, 25--3--3
Jun, 25--4--4
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 28, 2025JMP Securities$254.00$123.02106.47%106.47%
Oct 21, 2025Leerink Partners$160.00$134.0019.40%30.06%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 28, 2025CitigroupOutperformupgrade
Dec 02, 2024OppenheimerOutperformOutperformhold
Jun 13, 2024OppenheimerOutperformOutperformhold
Mar 14, 2024JMP SecuritiesMarket OutperformMarket Outperformhold
Sep 08, 2023SVB LeerinkOutperformupgrade
Sep 08, 2023MoffettNathansonOutperformupgrade
Mar 23, 2023JefferiesBuyBuyhold
Nov 16, 2022JMP SecuritiesMarket Outperforminitialise
Dec 20, 2021OppenheimerOutperforminitialise

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.24$-1.29----
Avg Forecast$-1.40$-0.93$-0.57$-0.62$-0.93$-1.01
High Forecast$-1.30$-0.84$-0.41$-0.15$-0.33$-0.35
Low Forecast$-1.50$-1.07$-0.68$-1.09$-1.53$-1.66
Surprise %-11.43%38.71%----

Revenue Forecast

$0 $6M $12M $18M $24M $30M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$10.09M$4.91M----
Avg Forecast$8.53M$5.09M$900.00K$8.25M$10.75M$19.50M
High Forecast$9.97M$5.60M$1.35M$12.38M$16.13M$29.25M
Low Forecast$7.40M$4.51M$450.00K$4.13M$5.38M$9.75M
Surprise %18.29%-3.58%----

Net Income Forecast

$-65M $-53M $-41M $-29M $-17M $-5M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-47.92M$-53.04M----
Avg Forecast$-53.79M$-39.43M$-25.61M$-36.13M$-35.81M$-38.70M
High Forecast$-49.97M$-32.37M$-15.75M$-5.65M$-12.54M$-13.55M
Low Forecast$-57.60M$-41.36M$-26.34M$-41.84M$-59.09M$-63.86M
Surprise %-10.91%34.52%----

SPRB Forecast FAQ

Is Spruce Biosciences stock a buy?

Spruce Biosciences stock has a consensus rating of Hold, based on 10 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 2 Buy, 8 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Spruce Biosciences is a neutral investment for most analysts.

What is Spruce Biosciences's price target?

Spruce Biosciences's price target, set by 10 Wall Street analysts, averages $207 over the next 12 months. The price target range spans from $160 at the low end to $254 at the high end, suggesting a potential 68.27% change from the previous closing price of $123.02.

How does Spruce Biosciences stock forecast compare to its benchmarks?

Spruce Biosciences's stock forecast shows a 68.27% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Spruce Biosciences over the past three months?

  • October 2025: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.

What is Spruce Biosciences’s EPS forecast?

Spruce Biosciences's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.57, marking a -55.81% decrease from the reported $-1.29 in 2024. Estimates for the following years are $-0.62 in 2026, $-0.93 in 2027, and $-1.01 in 2028.

What is Spruce Biosciences’s revenue forecast?

Spruce Biosciences's average annual revenue forecast for its fiscal year ending in December 2025 is $900K, reflecting a -81.67% decrease from the reported $4.91M in 2024. The forecast for 2026 is $8.25M, followed by $10.75M for 2027, and $19.5M for 2028.

What is Spruce Biosciences’s net income forecast?

Spruce Biosciences's net income forecast for the fiscal year ending in December 2025 stands at $-25.613M, representing a -51.71% decrease from the reported $-53.036M in 2024. Projections indicate $-36.125M in 2026, $-35.815M in 2027, and $-38.703M in 2028.